Analysts Turned Bullish on These 10 Stocks on Tuesday

8. Zimmer Biomet (NYSE:ZBH)

Average Upside Potential: 13%

Wells Fargo analyst Larry Biegelsen upgraded Zimmer Biomet to Overweight from Equal Weight on November 17 and set a price target of $123, up from $113. He pointed to the launch of the Monogram robot in the first half of 2027 as a fix for knees, the company’s weak spot.

Zimmer Biomet makes artificial knees, hips and other orthopedic implants, along with sports medicine, trauma and spine products. Knees are the line holding the numbers back. Their sales fell 3.1% in the third quarter of 2026, while hips grew 6.0%, and the business covering sports medicine, extremities and trauma also grew.

The company reported those results on November 4. Net sales rose in constant currency, which leaves out the effect of exchange rates, and the company raised its 2026 adjusted earnings per share guidance to a range of $8.50 to $8.60, along with its outlook for reported revenue growth. Chief Executive Officer Ivan Tornos said the company was “very pleased with our solid third quarter results.” Wells Fargo’s upgrade rests on the view that the rest of the business can keep growing while knees recover.

7. Centene (NYSE:CNC)

Average Upside Potential: 13%

Bernstein raised its price target on Centene to $90 from $79 on November 17 and kept its Outperform rating. The firm pointed to a recovery in the company’s Medicaid business after its results for the third quarter of 2026, which Centene reported on October 27.

Centene runs government-sponsored health plans, including Medicaid, Medicare and commercial coverage. In the third quarter of 2026, it earned adjusted earnings of $0.58 per share, and it raised its 2026 adjusted earnings guidance to above $5.20. On a GAAP basis, it reported a loss of $0.14 per share. It also said it had cut debt by $1.1 billion since June 30.

A new risk arrived on November 18, when the Centers for Medicare & Medicaid Services proposed a rule that would tighten oversight of Medicare, Medicaid, the Children’s Health Insurance Program and the health insurance marketplace, with more audits of insurers and a way for the agency to recover improper payments. Public comment on the proposal is open until January 19, 2027. We covered the turnaround playbook Centene handed to a new technology chief in an earlier piece.

6. TIM (NYSE:TIMB)

Average Upside Potential: 15%

Itau BBA analyst Maria Infantozzi upgraded TIM to Outperform from Market Perform on November 17 and raised her price target to R$25 from R$23, citing downside protection and the potential for higher payouts to shareholders.

TIM provides mobile, internet and ultra-broadband services in Brazil, including fixed broadband under the TIM Ultrafibra name. In the third quarter of 2026, net revenue rose 5.3% and normalized EBITDA, a profit measure that leaves out one-time items, also rose. Normalized net income fell 7.8%, which is the weak spot in the report. Reported net income, before those adjustments, was lower still. Itau BBA’s call came after TIM reported on November 9 and filed the results with the SEC on a Form 6-K. Reported amounts here are in Brazilian reais. Operating free cash flow rose, however, and that cash is what funds the payouts Itau BBA expects.

TIM guided to shareholder remuneration of R$5.3 billion to R$5.5 billion for 2026, and its net debt relative to normalized EBITDA was lower than in June, which leaves room for payouts. The board approved a new buyback program on August 19.

5. Nucor (NYSE:NUE)

Average Upside Potential: 23%

Morgan Stanley upgraded Nucor to Overweight from Equalweight on November 17 and raised its price target to $310 from $300, pointing to lower capital spending.

Nucor makes steel and steel products through three segments: steel mills, steel products and raw materials. In the third quarter of 2026, it earned $5.80 per diluted share on net sales of $11.25 billion, up from $2.63 per share a year earlier, and steel mill shipments reached 7,231 thousand tons, up from 6,428 thousand tons a year earlier. Over the first nine months of 2026, free cash flow came to $2.66 billion, and the company returned cash to shareholders, much of it through share repurchases.

Nucor’s new sheet mill in West Virginia had its first heat in September. In Morgan Stanley’s view, lower capital spending leaves more cash for buybacks and dividends. Nucor reported those results on October 26 and said it expects fourth-quarter earnings to be in line with or modestly higher than the third quarter. Our piece on Nucor’s strong shipments and the questions around its third-quarter guidance covers the debate over that outlook.